During the past decade preclinical studies have defined many of the mechanisms used by
tumours to hijack the skeleton and promote bone metastasis. This has led to the …

Bone metastases (BM) are a common complication of cancer, whose management often
requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with …

Highlights•The clinical course of advanced cancer for many patients with bone metastases
can be transformed through optimum multidisciplinary management.•Bone-targeted agents …

Background Patients with multiple myeloma treated with lenalidomide maintenance therapy
have improved progression-free survival, primarily following autologous stem-cell …

Background Multiple myeloma is characterised by monoclonal paraprotein production and
osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression …

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent
genetic aberrations is required as outcomes are variable despite apparent similar staging …

Bone metastasis is a major cause of morbidity in persons with cancer. Complications include
pain, impaired mobility, pathological fracture, spinal cord compression, cranial nerve …

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These
neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone …